|
Oct 9
|
Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook
|
|
Oct 7
|
ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis
|
|
Jun 21
|
ALK upgrades its full-year revenue and earnings outlook
|
|
Jun 21
|
ALK provides update on regulatory process for the house dust mite allergy tablet in China
|
|
Feb 16
|
Annual General Meeting in ALK-Abelló A/S on 14 March 2024
|
|
Dec 20
|
ALK – Financial calendar for the 2024 financial year
|
|
Oct 11
|
Large Phase 3 clinical trial successfully meets primary endpoint, confirming the potential of ALK’s tree tablet in children
|